Persistent Atrial Fibrillation

A platform with a mapping system and a large-tip catheter with dual pulsed field and radiofrequency energies was noninferior to a conventional radiofrequency ablation system for treatment of persistent atrial fibrillation, data show.

Persistent atrial fibrillation was associated with worse outcomes and less quality of life benefit after catheter ablation compared with paroxysmal AF, researchers reported.

In a small, single-center trial, the novel Marshall-Plan ablation strategy improved 10-month arrhythmia recurrence compared with pulmonary vein isolation alone for persistent atrial fibrillation, a speaker reported.

Comparing procedural time between conventional pulmonary vein isolation vs. very high-power radiofrequency delivery in AF patients.

A novel catheter for very high-power short-duration ablation for pulmonary vein isolation in patients with atrial fibrillation modestly reduced procedure time compared with standard ablation, according to data from the POWER PLUS trial.

In patients with atrial fibrillation and cancer, non-vitamin K antagonist oral anticoagulants outperformed warfarin in thrombotic and bleeding endpoints, according to findings published in Stroke.

Freedom from AF after thoracoscopic surgical ablation vs. catheter ablation in patients with long-standing persistent AF.

Johnson & Johnson Medical Devices Companies and Biosense Webster announced that an ablation catheter to treat patients with persistent atrial fibrillation has been approved by the FDA.

Thoracoscopic surgical ablation for long-standing persistent atrial fibrillation was not superior to catheter ablation in freedom from arrhythmia of at least 30 seconds or burden reduction of at least 75%, researchers reported.